Abstract
Use Cases
Drawing on both clinical background and translational research experience, we developed a set of use cases for pharmacogenomic information. Uses cases were defined from the perspective of professionals who are aware of the importance of pharmacogenomics, but need assistance in finding details relevant for specific clinical questions. These use cases were written and refined iteratively, without reference to any available information model. Once written, the queries were translated into an informal query notation, which will be used as the basis for eventual translation into SPARQL queries against an RDF knowledge base.
Mapping the FDA biomarker table
Data from the FDA's pharmacogenomic biomarker table 1 was downloaded and provided to a clinical pharmacologist (PEE) and a translational researcher with a background in pharmacogenomics (RRF) for review. Biomarkers in the table were mapped, where possible, to appropriate genes and proteins in the Protein Ontology 2 , official gene symbols maintained by the HUGO Gene Nomenclature Committee (HGNC) 3 , and biomarker identifiers in PharmGKB 4 . Specific variant alleles, fused genes, and chromosomal deletions and translocations were noted but not mapped to any external data source in this iteration of development.
Retrieval of product label sections referenced by the FDA biomarker table
The FDA requires industry to submit drug product labels using an Health Level Seven standard called Structured Product Labeling 5 . An SPL is an XML document written in the standard that specifically tags the content of each product label section with a unique code from the Logical Observation Identifiers Names and Codes (LOINC®) vocabulary 6 . The SPLs for all drug products marketed in the United States are available for download from the National Library of Medicine's DailyMed resource 7 . As part of a separate ongoing project we have built a resource called LinkedSPLs that provides a Linked Open Data 8 representation of the SPLs for all marketed prescription and over-the-counter drug products 9 . We have found that the LinkedSPLs resource makes it simple to retrieve content from specific product label sections along with a variety of SPL meta-data; a task that is more challenging to do by processing the SPL documents directly. The FDA pharmacogenomics biomarker table lists one or more product label sections for each active ingredient/biomarker combination present in the table. Most active ingredients in the table are a component of more than one drug product and some are used in both prescription and over-the-counter products. The FDA's description of the table makes it clear that the references are to sections in prescription drug products. However, no guidance is given on whether one can expect the same pharmacogenomics information across all sections for a given active ingredient. To address this issue, we randomly selected one representative section for each section listed in a row of the FDA's table. Section retrieval was done using a Python 10 script that queried the LinkedSPLs resource. The content for each section was stored in a text file, named so that we could identify both the product label from which it was extracted and the active ingredient/biomarker pair that is associated with it in the table. In accordance with the recommendations of a recent FDA draft guidance, 11 some companies have included a "Pharmacogenomics" section in newly-submitted SPLs. Our script issued a separate query for the text of one representative Pharmacogenomics section for every drug product label in which this section was included. The use cases were used along with several of the representative product label pharmacogenomics statements to define a semantic model of the pharmacogenetic content found within SPLs (i.e., the focus of model development was on pharmacogenomics content present in the SPLs). Relevant sentences were examined to identify referenced entities and relationships, which were modeled using the Cmap concept mapping tool 12 . We chose this informal modeling approach to enable rapid development of the model which we plan to make more formal as iterative refinement provides input from perspectives relevant to both pharmacological and translational viewpoints.
Development of a semantic model of pharmacogenomic information

Manual extraction and annotation of pharmacogenomics statements
Five pharmacist annotators independently extracted and annotated pharmacogenomics statements from a subset of the product label sections that were cited in the FDA's table. The sections were chosen based on the anticipated clinical relevance of the pharmacogenomics statements in pharmacy practice. The annotators were trained according to guidelines developed for this effort which were provided for their reference. The primary units of annotation were pharmacogenomics statements, defined as a sentence or sequence of sentences (i.e., a phrase) published in an FDAapproved drug package insert that mentions a pharmacogenomics biomarker and (in most cases) provides some information on the importance of that biomarker for use of the drug. The annotators described pharmacogenomics statements using a variety of attributes from the semantic model, including the relevant biomarker; the medication of interest; the variant of interest; pharmacokinetic and pharmacodynamic effects; relevant patient state, medical conditions or side effects; and recommendations for monitoring, drug selection, dose selection, or testing. Annotation was done using the Knowtator plug-in 13 for the Protégé modeling tool.
Results
Use Cases
A total of 13 clinical and translational use cases were identified (see Table 1 rd 2012. For all of the drugs listed in the table but two (galantamine and trimipramine), the query was able to return from one to many (>40) sections depending on the number of products containing a drug, and the number of SPLs for those products that provided a relevant section (some SPLs are missing sections). The failure to retrieve sections for galantamine and trimipramine might have been due to the use in the SPL of LOINC codes other than those intended for the cited sections.
a Our query for "Pharmacogenomics" sections returned only three results; two for products containing the drug cisplatin (Platinol®) and Platinol-AQ), and one for a drug containing carisoprodol and aspirin. Co-authors PE and RF selected 9 high priority drugs from the FDA biomarker table and investigator RDB randomly selected twenty-nine representative prescription drug product label sections for manual annotation from the set of sections cited in the FDA's Pharmacogenomics knowledge model The current knowledge model (partially shown in Figure 2 ) is available at http://purl.org/net/linkedspls/pharmgxfall-2012. The focus of the model is the SPL pharmacogenetic statement, which applies to a pharmacologic entity of interest, refers to a specific biomarker, describes pharmacodynamic and/or pharmacokinetic effects, and makes monitoring, dosage, and/or drug selection recommendations.
Manual extraction and annotation of pharmacogenomics statements
The five pharmacists identified a total of 213 pharmacogenomics statements in the 29 sections they were assigned to annotate. The results are summarized in the box to on the right in Figure 1 . As the figure shows, at least two pharmacists agreed that 11 sections (five drug product labels) contained dosage recommendations, five sections seven sections (three drug product labels) provided recommendations for genetic testing, and three sections (in two drug product labels) provided specific monitoring recommendations. Additionally, pharmacological context was added regarding whether impact of the pharmacogenomic information involved altered pharmacokinetics (14 sections in six drug product labels) and/or pharmacodynamics (22 sections in nine drug product labels). Interestingly, some sections listed in the FDA biomarker table as containing pharmacogenomic recommendations received no annotations by any of the five pharmacists (e.g., the citalopram Drug Interactions section for CYP2C19 and CYP2D6). Discussion A semantic model of pharmacogenomics statements in product labels has the potential to make the information and recommendations that are currently buried within product labeling actionable through structured annotations. While our field test only focused on a small set of product label sections, the range of annotations identified suggest that the model has the potential to more directly answer questions regarding drug and dosage selection, genetic test recommendations, pharmacological consequences of genetic variation, and associated medical conditions. For example, clinicians and translational researchers seeking pharmacogenomics information from the product label on warfarin would have to integrate the text contained within the Dosage and Administration, Precautions, Clinical Pharmacology sections of the drug label regarding two biomarkers CYP2C9 and VKORC1 to gain an understanding of the potential impact of genetic variants on drug response. The annotations created in this study succinctly state that variants in CYP2C9 impact pharmacokinetics (decrease metabolism) and consequently drug response, while VKORC1 only impacts pharmacodynamics. For both biomarkers, specific dose levels and a change in monitoring are recommended, but no alternative drug therapy or specific testing recommendations are made. Similarly, annotations created for codeine identified that CYP2D6 variants alter pharmacokinetics (increasing metabolism), increase the risk of toxicity, and that dose reductions are suggested, as well as the additional specific monitoring recommendation in special populations (nursing mothers). Finally, in 56 instances within the 29 sections, annotators noted medical conditions that were either important for identifying subpopulations impacted by a pharmacogenomic biomarker, or that were a consequence of a variant. This allows for future mapping to medical ontologies or queries across different biomarkers for effects such as "which biomarkers increase the likelihood of drug hypersensitivity?" While not the focus of this study, the work also identified some data quality issues within the FDA table and the mapping of external resources. Several of the drug product label sections listed in the FDA table contained no pharmacogenomics information according to a consensus of our pharmacist annotators. Anecdotally, in attempting to reconcile these perceived errors, two reviewers also identified sections within drug product labels that were not listed in the FDA biomarker table. Similarly, mapping inconsistencies were uncovered while attempting to resolve linkages between biomarkers in the FDA table, HGNC gene symbols, and PharmGKB. For example, the HGNC gene symbol of CD20 antigen, a pharmacogenomic biomarker within the tositumomab label, is MS4A1. PharmGKB currently links this drug product label to the gene MS4A2 which, although an accepted alias for MS4A1, is an independent gene symbol on its own.
Conclusions
Through ongoing work, our team will further refine the semantic model in parallel to the use cases and will generate annotations for the remaining sections. We believe adding structure to the rich pharmacogenomics data currently scattered throughout the appropriate sections of the drug product labels will unlock the potential of using this rich information to advance translational research and patient care.
